Shenzhen Cell Therapy Firm PriMedix Launches A-Share IPO Preparations

On April 18, 2024, the China Securities Regulatory Commission (CSRC) disclosed on its official website that Shenzhen Pregene Biopharma Co., Ltd. ("Pregene") had registered for listing guidance. The guiding institution is Shenwan Hongyuan Securities, and the dispatched institution is the Shenzhen CSRC Bureau.

Source of the image: Official website of the CSRC

The official website information shows,PregenePregene is a national high-tech enterprise, the Guangdong Provincial Cell and Gene Therapy Innovative Drug Engineering Research Center, and a Shenzhen-based specialized and innovative enterprise. Its investors include the National SME Development Fund, Guoke Jiahe Fund under the Chinese Academy of Sciences, Haier Capital, Shenzhen Capital Group, Huabang Health, and others. With years of deep cultivation in the field of cell and gene therapy drugs, its product pipeline includes CAR-T and CAR-NK drugs targeting multiple sites, with indications covering various therapeutic areas such as hematological tumors, solid tumors, and autoimmune diseases. Pregene adheres to the development strategy and path of platforming technology, productizing platforms, commercializing products, and internationalizing commerce. It is currently a leading innovative cell drug company in the industry that has achieved multi-regional global licensing for CAR-T cell drugs.

The official website information shows,PregeneFocused on the research and development of cell and gene therapy drugs, significant progress has been achieved. In March 2020, the BCMA-targeted CAR-T cell drug for treating multiple myeloma received clinical approval from the NMPA. This is the first CAR-T cell drug clinical approval in South China, demonstrating excellent safety and efficacy based on clinical trial results.